BIOINVENT INTERNATIONAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.95 SEK | +11.40% |
|
+30.02% | +26.32% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Companyâs operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
Calendar
2024-04-24
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
21.5
SEK
Average target price
83
SEK
Spread / Average Target
+286.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.32% | 129M | |
| -3.56% | 102B | |
| +2.48% | 96.84B | |
| -0.44% | 21.48B | |
| -18.38% | 20.82B | |
| -7.45% | 18.6B | |
| -40.70% | 16.81B | |
| -25.78% | 13.78B | |
| +0.45% | 13.4B | |
| +22.71% | 11.06B |
- Stock Market
- Equities
- BINV Stock
- News BioInvent International AB
- BioInvent International : , Transgene Win US FDA Nod For Phase 1/2a Study of Cancer Vaccine
